Zymeworks Inc., a Vancouver, BC, Canada-based biotherapeutics company focused on the development of bi-specific antibody therapeutics and multi-valent protein therapeutics, has raised $11.0m in funding.
The round was led by the Advanced Biotechnologies Venture Fund group of funds, with participation from both new and existing private shareholders.
The company intends to use the capital to advance its lead oncology candidates through late stage preclinical studies and into the clinic.
Led by Dr. Ali Tehrani, President and CEO, and Neil Klompas, Chief Financial Officer, Zymeworks is developing antibody therapeutics for the treatment of oncology, autoimmunity and inflammatory diseases.
Its proprietary ZymeCAD™ structure-guided protein engineering technology and its novel Azymetric™ and AlbuCORE™ platforms enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications.
FinSMEs
06/09/2012